Novartis Ag (NVS) Cash & Current Investments (2009 - 2025)

Novartis Ag's Cash & Current Investments history runs 13 years deep, the most recent figure standing at $2.7 billion for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 19.51% year-over-year to $2.7 billion; the TTM figure through Dec 2025 stood at $2.7 billion (up 19.51% YoY), while the FY2025 annual figure was $2.7 billion, up 19.51% from the prior year.
• Cash & Current Investments came in at $2.7 billion for Q4 2025 at Novartis Ag, down from $6.7 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $28.3 billion in Q4 2021 to a low of $6.0 million in Q1 2021.
• A 5-year average of $6.4 billion and a median of $3.2 billion in 2022 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments sank 92.11% in 2021 and jumped 1066.67% in 2022, its largest moves.
• Novartis Ag's Cash & Current Investments stood at $28.3 billion in 2021, then sank by 33.18% to $18.9 billion in 2022, then decreased by 23.78% to $14.4 billion in 2023, then tumbled by 84.47% to $2.2 billion in 2024, then rose by 19.51% to $2.7 billion in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $2.7 billion, $6.7 billion, and $2.2 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison